Barclays analyst Jonathan Eckard has boosted the price target for shares of Advaxis, Inc. (NASDAQ:ADXS), from $15 to $20, while reiterating a Buy …
Barclays analyst Jonathan Eckard is cautiously optimistic now that Ionis Pharmaceuticals (NASDAQ:IONS) has tested its pipeline drug nusinersen, a short stretch of nucleic …
